Literature DB >> 23559740

Issues about diagnosis and treatment of toxic epidermal necrolysis.

Beatriz Besteiro1, Maria Madruga, Rita Galeiras.   

Abstract

Entities:  

Year:  2012        PMID: 23559740      PMCID: PMC3610465          DOI: 10.4103/0972-5229.106515

Source DB:  PubMed          Journal:  Indian J Crit Care Med        ISSN: 0972-5229


× No keyword cloud information.
Sir, We would like to make the following comments regarding the case recently published in your journal “Carbamazepine-induced toxic epidermal necrolysis.”[1] The authors describe a clinical picture, clearly suggestive of toxic epidermal necrolysis (TEN), with compatible mucocutaneous lesions and positive Nikolsky's sign, which is characteristic but not specific to this disease.[2] The clinical picture begins less than three weeks after initiating carbamazepine, a drug, that is clearly related to TEN.[3] However, confirmation of the diagnosis requires a cutaneous biopsy for conventional histopathology and immunohistochemistry to rule out other conditions that may be clinically similar to or even completely indistinguishable from TEN (staphylococcal toxic shock syndrome, linear IgA dermatosis, bullous pemphigus, etc.).[2] TEN is known to be a drug reaction based on clinical experience. Recently, the term “Acute Syndrome of Apoptotic Pan-Epidermolysis” (ASAP)[4] was proposed to include all clinical situations of massive and acute epidermal cleavage resulting from apoptotic injury. ASAP includes conditions such as drug-induced TEN, TEN-like lupus erythematosus, TEN-like pseudoporphyria, and graft versus host disease. Even with histopathology and immunohistochemistry, differential diagnosis may be impossible, and the clinical course may vary.[4] As the authors themselves point out, treatment of TEN with corticosteroids is still an unresolved issue. Although the use of corticosteroids used to be widespread, the lack of clinical evidence regarding their efficacy and the fact that they have been linked, in some studies, with increased infections and mortality, makes their use in these patients inadvisable.[5] However, data from a European retrospective study suggest that corticosteroid treatment may have a beneficial effect, although a uniform dose-dependent benefit was not observed.[5] Similarly, the results from a small single-center retrospective study suggest that treatment with “pulses” of high doses of dexamethasone may be beneficial.[6] A randomized controlled study is needed to clarify this issue.
  6 in total

1.  Toxic epidermal necrolysis-like cutaneous lupus erythematosus: A series of three patients.

Authors:  Claudia G C Cisneros; Ricardo Romiti; Cláudia G Santi; Valéria Aoki; Neusa Y S Valente; Marcello M S Nico
Journal:  Acta Derm Venereol       Date:  2010-03       Impact factor: 4.437

Review 2.  Severe cutaneous adverse reactions: acute generalized exanthematous pustulosis, toxic epidermal necrolysis and Stevens-Johnson syndrome.

Authors:  Thomas Harr; Lars E French
Journal:  Med Clin North Am       Date:  2010-07       Impact factor: 5.456

3.  Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study.

Authors:  Jürgen Schneck; Jean-Paul Fagot; Peggy Sekula; Bruno Sassolas; Jean Claude Roujeau; Maja Mockenhaupt
Journal:  J Am Acad Dermatol       Date:  2007-10-04       Impact factor: 11.527

4.  Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study.

Authors:  Maja Mockenhaupt; Cecile Viboud; Ariane Dunant; Luigi Naldi; Sima Halevy; Jan Nico Bouwes Bavinck; Alexis Sidoroff; Jürgen Schneck; Jean-Claude Roujeau; Antoine Flahault
Journal:  J Invest Dermatol       Date:  2007-09-06       Impact factor: 8.551

5.  Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis.

Authors:  Sylvia H Kardaun; Marcel F Jonkman
Journal:  Acta Derm Venereol       Date:  2007       Impact factor: 4.437

6.  Carbamzepine-induced toxic epidermal necrolysis.

Authors:  Nithyananda K Chowta; Mukta N Chowta; John Ramapuram; Pramod Kumar; Abul Fazil
Journal:  Indian J Crit Care Med       Date:  2011-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.